Disaster resilience and recovery nonprofit SBP has hired Leigh Thorpe as its first chief advancement officer to oversee fundraising and marketing efforts. Thorpe was most recently vice president of ...

Carboranes are molecules composed of carbon, boron and hydrogen atoms that are proving to have applications of great interest ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...

A mother's ongoing battle with a rare disease has created significant hardship for her family. The family's 11-year-old son, Myles, helps his father care for his mother and younger sister. Unable to ...

NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid Oral presentation at the 2026 Annual ...

A newly discovered genetic link between cat and human cancer may have major implications for the disease’s treatment in both ...

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are ...

"I plan to make the most of my ‘bonus’ time for years to come," George Jerjian said about his brush with death ...

Chemotherapy drugs that target a common mutation in colorectal cancer rapidly lose efficacy in patients, leading to relapse.

Stopping cancer from coming back is the goal of new research from MUSC Hollings Cancer Center, where scientists are targeting cells that fuel the return of an aggressive pediatric brain tumor.

Chemotherapy drugs that target a common mutation in colorectal cancer rapidly lose efficacy in patients, leading to relapse.

A new study leverages a modified pyrvinium hybrid to block GLI and WNT pathways, halting pediatric medulloblastoma relapse.